Skip Navigation


Rheumatology Advance Access originally published online on February 24, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
43/5/626    most recent
keh136v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Giannouli, S.
Right arrow Articles by Moutsopoulos, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giannouli, S.
Right arrow Articles by Moutsopoulos, H. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2004; 43: 626-632
Rheumatology Vol. 43 No. 5 (c) British Society for Rheumatology 2004; all rights reserved

Clinical

Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study

S. Giannouli, M. Voulgarelis, E. Zintzaras1, A. G. Tzioufas and H. M. Moutsopoulos

Department of Pathophysiology, Medical School, National University of Athens, 1Biomathematics Laboratory, Medical School, University of Thesssaly, Larisa, Greece.

Correspondence to: H. M. Moutsopoulos, Department of Pathophysiology, Medical School, National University of Athens, M. Asias 75, Goudi 11527 Athens, Greece. E-mail: hmoutsop{at}med.uoa.gr

Objective. To determine the clinical aspects and evolution of autoimmune inflammatory manifestations (AIMs) in patients with myelodysplastic syndrome (MDS) and ascertain the prognostic implications of these manifestations in MDS.

Methods. Seventy patients diagnosed for MDS were enrolled in a prospective cohort study of 4-yr duration. Thirteen patients with AIMs were identified (group A). The remaining 57 MDS patients without AIMs constituted the control group (group B). Demographic, clinical features, laboratory data, treatment and outcome of all these cases were recorded.

Results. On comparing features between the two groups we were unable to identify any particular difference (P >= 0.05) concerning bone marrow blast count [odds ratio (OR) = 0.68], international prognostic scoring system (IPSS) (OR = 1.36), favourable cytogenetic abnormalities (OR = 0.52), leukaemic transformation (OR = 1.30) and survival (P = 0.76). Furthermore there was a significant difference in survival between low vs non-low IPSS patients for both groups (P<0.01).

Conclusion. In a 4-yr prospective study the prognosis of MDS patients with AIMs appeared to be closely related to the IPSS subcategory of the underlying haematological malignancy and not to the autoimmune process.

KEY WORDS: Myelodysplastic syndrome, Vasculitis, Relapsing polychondritis, Arthritis, Autoimmunity.

This paper is dedicated to the memory of the late M. Tsakopoulos, MD, Professor of Experimental Physiology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.